<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2EE67318-29A8-4239-8DC6-66250FF55A98"><gtr:id>2EE67318-29A8-4239-8DC6-66250FF55A98</gtr:id><gtr:name>Igennus Healthcare Nutrition</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCC23D44-DC2E-4B3C-8B75-DD25C8B4D4CE"><gtr:id>FCC23D44-DC2E-4B3C-8B75-DD25C8B4D4CE</gtr:id><gtr:name>Thetis Pharmaceuticals LLC</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FF42FA0-E5E6-4CD8-870A-2C1E5055F52F"><gtr:id>9FF42FA0-E5E6-4CD8-870A-2C1E5055F52F</gtr:id><gtr:name>University of Bradford</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2EE67318-29A8-4239-8DC6-66250FF55A98"><gtr:id>2EE67318-29A8-4239-8DC6-66250FF55A98</gtr:id><gtr:name>Igennus Healthcare Nutrition</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCC23D44-DC2E-4B3C-8B75-DD25C8B4D4CE"><gtr:id>FCC23D44-DC2E-4B3C-8B75-DD25C8B4D4CE</gtr:id><gtr:name>Thetis Pharmaceuticals LLC</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3B20713-956F-4D17-9AF7-B561CCBAE326"><gtr:id>E3B20713-956F-4D17-9AF7-B561CCBAE326</gtr:id><gtr:name>University of Bologna</gtr:name><gtr:address><gtr:line1>Via Irnerio 46</gtr:line1><gtr:postCode>40126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FF42FA0-E5E6-4CD8-870A-2C1E5055F52F"><gtr:id>9FF42FA0-E5E6-4CD8-870A-2C1E5055F52F</gtr:id><gtr:name>University of Bradford</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/12BDE253-AA20-4608-BEEB-DA3B9815F3C2"><gtr:id>12BDE253-AA20-4608-BEEB-DA3B9815F3C2</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Hull</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1002465"><gtr:id>DFF4F1AF-0522-464A-A444-46DBF8C33D2E</gtr:id><gtr:title>A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) preve</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1002465</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Scientific Abstract
Research design: A randomised, double-blind, placebo-controlled 2 x 2 factorial trials integrated into the screening and surveillance phases of the National Bowel Cancer Screening Programme (BCSP).
Study population: BCSP patients str</gtr:technicalSummary><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>912897</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bologna</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Gastroenterology</gtr:department><gtr:description>seAFOod Trial Biomarker analysis</gtr:description><gtr:id>A7C0DD8E-3720-4366-B0B0-1C461E8738F0</gtr:id><gtr:impact>Neoplasia 2010;12:618-27
Br J Pharmacol 2012;166:1724-37</gtr:impact><gtr:outcomeId>sqrRsMaPkpL-2</gtr:outcomeId><gtr:partnerContribution>biological sample handling, fatty acid measurement and lipidomic analyses</gtr:partnerContribution><gtr:piContribution>study design, sample collection and Trial organisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>seaFOod Trial link with MRC START programme to test improved materials for trial recruitment</gtr:description><gtr:id>9789D8DA-804A-4A80-ACD3-78DF2A94027B</gtr:id><gtr:impact>nil</gtr:impact><gtr:outcomeId>56d6c9cfd0a848.95905406-1</gtr:outcomeId><gtr:partnerContribution>worked with MRC START team to develop video and website material and submitted SA to REC.</gtr:partnerContribution><gtr:piContribution>Cluster randomised sites to use of multimedia materials for particpant recruitment within the seAFOod Trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Igennus Healthcare Nutrition</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>partnership with Igennus Healthcare Nutrition</gtr:description><gtr:id>8FDC05B3-3A61-439F-B244-D7A0FBE31BA2</gtr:id><gtr:impact>supply of capsules for continued recruitment</gtr:impact><gtr:outcomeId>5453a26cc48aa8.89000243-1</gtr:outcomeId><gtr:partnerContribution>Discount purchase of capsules and support developing MHRA CTA amendment</gtr:partnerContribution><gtr:piContribution>We obtained active EPA and placebo capsules from Igennus at cost price after the previous supplier to the seAFOod Trial (SLA Pharma AG) was unable to continue to supply IMP free of charge.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thetis Pharmaceuticals LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Consultancy for Thetis Pharma</gtr:description><gtr:id>614A4210-5D76-4F38-B00A-E18B01B44DCF</gtr:id><gtr:impact>nil</gtr:impact><gtr:outcomeId>58bfcf32e807f9.40412477-1</gtr:outcomeId><gtr:partnerContribution>Sharing of data</gtr:partnerContribution><gtr:piContribution>Advice on design of pre-clinical and clinical studies for omega-3 derivative IMP. Contribution to pre-clinical investigation of TP-252 efficacy for prevention of intestinal tumorigenesis in ApcD14 model</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Business, Management and Economics Sussex</gtr:department><gtr:description>seAFOod Trial TTR</gtr:description><gtr:id>20485E95-18A4-4214-A04F-4C57AC1FD8DF</gtr:id><gtr:impact>nil</gtr:impact><gtr:outcomeId>56d6cbd80c0428.07171719-1</gtr:outcomeId><gtr:partnerContribution>Interviews with me and collaborators</gtr:partnerContribution><gtr:piContribution>Contributed to MRC request to add to Tracking Translational Research project by Dr Michael Hopkins</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bradford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Therapeutics</gtr:department><gtr:description>seAFOod Trial Biomarker analysis</gtr:description><gtr:id>D8501F63-AF8B-44D0-901D-91A6B5B3AA28</gtr:id><gtr:impact>Neoplasia 2010;12:618-27
Br J Pharmacol 2012;166:1724-37</gtr:impact><gtr:outcomeId>sqrRsMaPkpL-1</gtr:outcomeId><gtr:partnerContribution>biological sample handling, fatty acid measurement and lipidomic analyses</gtr:partnerContribution><gtr:piContribution>study design, sample collection and Trial organisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public information website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C8721769-BEBC-4E41-9BA0-F86B5C6818C3</gtr:id><gtr:impact>CancerHelpUK information about seAFOod Trial

increased public (patient) awareness of Trial</gtr:impact><gtr:outcomeId>MWHt1iTqBjQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about Trial funding</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>6DEA675D-DDD2-4B61-A61C-53AFE34789E1</gtr:id><gtr:impact>written and audio media

none recognised</gtr:impact><gtr:outcomeId>bE2jAeETHS6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1496870</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>81CDD451-92BC-42CB-B9F0-4677DC2878E5</gtr:id><gtr:outcomeId>56d6c69d00a210.48023457</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant scheme</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Leeds Teaching Hospitals NHS Trust</gtr:fundingOrg><gtr:id>89D6004C-AA89-456C-9E07-FF06B91B8E44</gtr:id><gtr:outcomeId>5453a69327a8d2.18044579</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>216941</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Yorkshire Cancer Research Project Grant</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>E2D17189-417B-4A98-9A17-6149D957CBBB</gtr:id><gtr:outcomeId>bCtSSjbF7dq</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8AEC79A2-B565-4D71-B2EC-E254291A0A84</gtr:id><gtr:title>A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f13b1621a3cfc3cea05b8090aaf99c6"><gtr:id>0f13b1621a3cfc3cea05b8090aaf99c6</gtr:id><gtr:otherNames>Watson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5aa517929389a4.42728614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AED7B71-6E52-4DB8-92F6-03F98664AED8</gtr:id><gtr:title>Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases.</gtr:title><gtr:parentPublicationTitle>Prostaglandins, leukotrienes, and essential fatty acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f13b1621a3cfc3cea05b8090aaf99c6"><gtr:id>0f13b1621a3cfc3cea05b8090aaf99c6</gtr:id><gtr:otherNames>Watson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0952-3278</gtr:issn><gtr:outcomeId>58bfccd00dc641.20446491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81641A46-22D6-4EC8-9157-55DADEFD0F39</gtr:id><gtr:title>Successful delivery of clinical gastroenterology studies in the UK.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56d6c3c51a7218.91830892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05D52A41-30D2-4D31-A51B-D4207FC4FD13</gtr:id><gtr:title>A liquid chromatography-tandem mass spectrometry method to measure fatty acids in biological samples.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d47d7872f820ded23843b6f4a71e596e"><gtr:id>d47d7872f820ded23843b6f4a71e596e</gtr:id><gtr:otherNames>Volpato M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>5aa5171a57f119.59102382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81EFE13A-A906-47AF-8E90-C93E4E8A3094</gtr:id><gtr:title>Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/967494d8c6f90da025574a8d84906e42"><gtr:id>967494d8c6f90da025574a8d84906e42</gtr:id><gtr:otherNames>Burr N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>5453a56f9681b3.25463121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F733133C-CDC8-4A3D-99B0-387379C99C9A</gtr:id><gtr:title>Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d47d7872f820ded23843b6f4a71e596e"><gtr:id>d47d7872f820ded23843b6f4a71e596e</gtr:id><gtr:otherNames>Volpato M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58bfccd062be69.34796463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>059667EB-3C93-42AF-BD00-DF86E34B0F00</gtr:id><gtr:title>A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac6910d81a01c4daa65369186e4ca347"><gtr:id>ac6910d81a01c4daa65369186e4ca347</gtr:id><gtr:otherNames>Hull MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_12568_28_23895505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7371A3D7-2541-4DCA-BC3E-EDD5AE7A784F</gtr:id><gtr:title>A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc?14/+ mice.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be667b3bec8ad432238962f345d6883d"><gtr:id>be667b3bec8ad432238962f345d6883d</gtr:id><gtr:otherNames>Nakanishi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>5aa517b650fc56.63725901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37CAA2BA-8CD7-4908-8D3E-F408F6AE8538</gtr:id><gtr:title>Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/817523c6aecb5dda59ed3eb83e20f33c"><gtr:id>817523c6aecb5dda59ed3eb83e20f33c</gtr:id><gtr:otherNames>Gill MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56d6c3c54b9468.34493225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F50C013-DA41-4CC3-8353-E4DDD18B7353</gtr:id><gtr:title>No drug, no trial? Think again!</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d19ae607b34e1883938855bbbd4a527"><gtr:id>8d19ae607b34e1883938855bbbd4a527</gtr:id><gtr:otherNames>Sprange K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d6d2f1dec4c7.27972317</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1002465</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>